Meningococcal Vaccines Session

David S. Stephens, M.D.
Chair, Meningococcal Work Group

Advisory Committee on Immunization Practices
June 27, 2019
Serogroup B meningococcal (MenB) booster doses in persons at increased risk for serogroup B meningococcal disease

- ACIP recommends a MenB primary series for persons at increased risk for serogroup B meningococcal disease.
  - Booster doses not currently recommended for persons who remain at increased risk.

- At the February 2019 meeting, data was presented to ACIP on:
  - Persistence of the immune response following MenB primary vaccination
  - Immunogenicity, safety, and persistence of a MenB booster dose
  - Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) and Evidence to Recommendations (EtR) framework for MenB booster doses
  - Work Group interpretation and policy options for MenB booster doses
Meningococcal Vaccines Work Group Activities

- Reviewed ACIP feedback received during the February 2019 meeting.

- Discussed potential programmatic challenges of MenB booster doses.
  - Specific updates proposed to CDC’s outbreak guidance related to booster dose implementation during outbreaks.

- Developed an updated ACIP statement to harmonize existing meningococcal vaccine recommendations and potential MenB booster recommendations into a single document.
Agenda

- Summary of immunogenicity and safety data, GRADE, EtR, and policy options for MenB booster doses in persons at increased risk.
  - Sarah Mbaeyi, CDC/NCIRD

- Updated ACIP statement for meningococcal vaccination in the United States.
  - Sarah Mbaeyi, CDC/NCIRD
Votes

- Vote #1: MenB booster doses in persons at increased risk for serogroup B meningococcal disease.
- Vote #2: Updated ACIP meningococcal vaccines statement.
Work Group Members

ACIP Members
• David Stephens (Chair)
• Kelly Moore
• Hank Bernstein
• Veronica McNally

Ex Officio Members
• Lucia Lee (FDA)
• Anuja Rastogi (FDA)
• Ruth Brenner (DOD)

CDC Work Group Lead
• Sarah Mbaeyi (CDC/NCIRD)

Liaison Representatives
• Nina Ahmad (AAFP)
• Oliver Baclic (NACI)
• Carol Baker (IDSA)
• Susan Even (ACHA)
• Rachel Herlihy (IAC)
• Nneka Holder (SAHM)
• Martin Luta (CSTE)
• Ruth Lynfield (AAP)
• Paul McKinney (APTR)
• William Schaffner (NFID)

Consultants
• Mike Brady
• Kathleen Harriman
• Mary Healy
• Cody Meissner
• Paul Offit
• Lorry Rubin
CDC contributors

- Alison Albert
- Amy Blain
- Catherine Bozio
- Nicole Brown
- Amanda Cohn
- Jonathan Duffy
- LeAnne Fox
- Rachel Gorwitz
- Susan Hariri
- Angela Jiles
- David Kim
- Andrew Kroger
- Jessica MacNeil
- Lucy McNamara
- Sara Oliver
- Ismael Ortega-Sanchez
- Heather Reese
- Xin Wang
- Lauren Weil
- Charnetta Williams
For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.